ReviewNeurology. Clinical practice2022
Inhaled Levodopa (CVT-301) for the Treatment of Parkinson Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Review in Neurology. Clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Improvement in Quality of Life and Non-Motor Symptoms Associated With OFF Episodes in People With Parkinson's Disease Treated With Inhaled Levodopa.European journal of neurology · 2026Article
- Review
- Clinical Use Patterns and Patient-Reported Experience with Inhaled Levodopa in Routine Practice: A Two-Center Study.Medical sciences (Basel, Switzerland) · 2026Observational
- Inhaled levodopa in Parkinson´s disease with motor fluctuations: post-commercialization experience in two movement disorders units.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Observational
- Parkinson's disease: pathogenesis and therapeutic strategies.Molecular biomedicine · 2026Review
- Pharmacotherapy of motor symptoms in early and mid-stage Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.Journal of neurology · 2024Article
- [Inhaled levodopa: from evidence to experience].Revista de neurologia · 2024Review
- Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System.Pharmaceutics · 2024Review
- Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.Drugs · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose of Review: To investigate the efficacy and safety of CVT-301 in treating motor fluctuation in patients with Parkinson disease (PD). Recent Findings: This study demonstrated that the CVT-301 group had a higher proportion of patients achieving an ON state than the placebo group (odds ratio [OR] = 2.68; 95% confidence interval [CI]: 1.86-3.86; Summary: CVT-301 had the potential to be an alternative or even a preferred treatment for motor fluctuation in patients with PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.